\r\n<\/a>\r\n<\/p>\n<\/div><\/section><\/div> <\/p>\n<\/div><\/section> <\/p>\n Tetra Pharm Technologies develops and manufactures pharmaceutical drugs targeting the endocannabinoid system for the treatment of neuropathic pain, sclerosis and mental health disorders.<\/p>\n<\/div><\/section> “The launch of our first product represents an important and significant milestone for Tetra Pharm Technologies. From a business perspective, it gives us the opportunity to further strengthen the company’s long-term research and development efforts, which is our primary focus<\/i>“, says Martin Rose, Chief Executive Officer, Tetra Pharm Technologies.<\/p>\n Tetra Pharm Technologies plans to expand sales of XATEPA\u00ae and launch the drug in a number of additional European and overseas markets in the near future.<\/p>\n “The suitability of the drug delivery system is often neglected at the expense of cannabinoid bioavailability. Our XATEPA\u00ae sublingual spray is devised as a so-called enabling technology to provide optimal conditions for cannabinoid uptake and thus efficacy. From a pharmaceutical science perspective, we are indeed very proud of this achievement, and we look forward to launch more innovative products targeting the endocannabinoid system<\/i>“, says Dr. Morten Alles\u00f8, Chief Scientific Officer, Tetra Pharm Technologies.<\/p>\n Tetra Pharm Technologies has entered into an agreement with PHOENIX Pharma-Einkauf GmbH\u00a0for the distribution of XATEPA\u00ae in Germany. PHOENIX Pharma-Einkauf GmbH\u00a0is one of Europe’s largest wholesale distributors of pharmaceutical and healthcare products.<\/p>\n “Germany is the largest market in Europe for pharmaceutical drugs<\/i>\u00a0based on cannabinoids, and we have positive expectations for the sales of XATEPA\u00ae. The partnership with <\/i>PHOENIX Pharma-Einkauf GmbH\u00a0regarding distribution to German pharmacies ensures access to the product for all doctors and their patients, and since we have eliminated any middlemen, we can deliver the product at a fair price<\/i>“, says Martin Caspersen, Chief Commercial Officer, Tetra Pharm Technologies.<\/p>\n For more information, please visit www.tetrapharm.eu<\/a><\/p>\n<\/div><\/section> <\/p>\n<\/div><\/section><\/div>\n","protected":false},"excerpt":{"rendered":" The Danish biotech company, Tetra Pharm Technologies, is launching its first product, XATEPA\u00ae, on the German market. XATEPA\u00ae is a pain-relieving pharmaceutical\u00a0drug based on cannabinoids.<\/p>\n","protected":false},"author":3,"featured_media":19372,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-19371","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-e-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19371"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=19371"}],"version-history":[{"count":1,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19371\/revisions"}],"predecessor-version":[{"id":19373,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19371\/revisions\/19373"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/19372"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=19371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=19371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=19371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nTetra Pharm Technologies launches first product in Germany<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\nThe Danish biotech company, Tetra Pharm Technologies, is launching its first product, XATEPA\u00ae, on the German market. XATEPA\u00ae is a pain-relieving pharmaceutical\u00a0drug based on cannabinoids.<\/b><\/h3>\n
\n
\n
\nShare this<\/h5>